Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.74

-1.3%

Dec 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2610)	9/28/2009 10:47:42 AM
From: Jibacoa	Read Replies (1) of 3722

PSDV is bouncing up without testing the support at the $4 level.<g> The stock is up 11.63% with volume about 1.5x its ADV bigcharts.marketwatch.com On Thursday last week, it reported its 4thQ results, which of course showed a good improvement from the $3.48 loss in 2008. The loss for the 4thQ this Yr. was only $0.03 <g> In 2008 there had been a $60.1M charge for impairment of good will. The revenues in the 4thQ were $3.2M vs.$2.7M in 2008. It ended the Yr. with $6.9M in cash PDSV has currently a PIII of Iluvien for the treatment of DME, which is expected to be completed this Yr. The trials are been carried out by Alimera, which plans to file an NDA in 2010 Besides its Durasert technology, in which Iluvien is based, PDSV also has another drug delivery platform in BioSilicon. In April 2010 PSDV is expected to receive $500Ks monthly, under a $15M conditional note issued by Almera and if Iluvien is approved, it is supposed to receive a $25M milestone payment and it would also be entitled to a 20% profit on the drug sales.<g> Iluvien delivers flucinolone acetonide by injection into the posterior chamber of the eye with an expected duration of 3 years. Diabetic macular edema is a potentially blinding disease, which affects more than 1M in the US and for which there isn't an FDA approved drug treatment. Alimera is also sponsoring studies to assess the safety and efficacy of Iluvien in wet and dry AMD and retinal vein occlusion. There is no ACTAY, but I will put a temporary target at $8 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next